UNSPSC 51401709: Olanzapine hydrochloride

This classification denotes an antipsychotic agent with the molecular formula C17H20N4S.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0Q8K2L0MC3. Most nations, for tariff and trade purposes, schedule olanzapine hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, OLANZAPINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC1CC2C(S1)NC3CCCCC3N=C2N4CCN(CC4)C.CL.

UNSPSC 51401709 Olanzapine hydrochloride is a Commodity code, but the recent state and local opportunities posted under it show no actual procurement activity for this specific pharmaceutical product. Instead, the three recent solicitations tag the code while purchasing naloxone and drug deactivation systems (Seminole County, Florida), exploring direct-to-manufacturer prescription programs (Texas Health and Human Services Commission), and procuring generic multi-source pharmaceuticals and over-the-counter products through a cooperative purchasing vehicle (Minnesota Multistate Cooperative Purchasing Alliance). The mismatch between the code's nominal scope and the actual work being solicited suggests the code sees little relevant recent activity at the state and local level, or that issuers are applying it incorrectly to broader pharmaceutical procurement categories.

The three opportunities reflect different procurement models and geographies. Seminole County's IFB (due July 26, 2023, though posted June 30, 2026) targets naloxone and drug deactivation systems for community health with quarterly deliveries to Sanford, Florida and includes FEMA compliance requirements. Texas HHS issued an RFI in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription contracting outside traditional pharmacy benefit manager channels, framing foundational market research rather than a formal award. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP, due March 26, 2026, seeks generic pharmaceuticals and OTC products through three authorized wholesalers for state and local government facilities in Minnesota and Oregon, with pricing weighted at 75 percent and contract award effective July 1, 2026. These opportunities reflect state departments and county health systems as the primary issuing bodies, with cooperative purchasing vehicles expanding reach across multiple jurisdictions. Activity is visible in Florida, Texas, and the Minnesota-Oregon cooperative region, though olanzapine hydrochloride itself does not appear as a line item in any recent solicitation reviewed.